ventional therapy, and those who relapse after combination chemotherapy, have a poor prognosis. The treatment of patients with relapsed/refractory Hodg-A major limitation of ABMT for relapsed/refractory Hodgkin's disease is disease recurrence post-transplankin's disease with high-dose chemotherapy and autologous bone marrow transplantation (ABMT) initially showed that tation. We retrospectively reviewed 68 patients undergoing ABMT from January 1987 to June l993. All high response rates were achievable. 4-9 These initial reports were frequently limited by small numbers of patients and received a uniform preparatory regimen (CBV). The median patient age was 30; 75% received prior radishort follow-up. More recently, several series with mature follow-up have reported that 25-50% of patients with ation therapy and all patients received prior chemotherapy. Thirty-one percent presented at the time of relapsed/refractory Hodgkin's disease treated with ABMT, with or without the use of peripheral blood progenitor cells transplantation with tumor masses larger than 10 cm. Sixty-two percent received autologous marrow alone (PBPC), are rendered disease-free. [10][11] [12] [13] [14] [15] [16] [17] [18] [19] The single most important reason for treatment failure is recurrence of and 38% PBPC with or without autologous bone marrow. Overall and progression-free survival are 43 and Hodgkin's disease post-transplantation. Relatively little data exist describing the outcome of 36% at 5 years. Median follow-up for survivors is 59 months. Multivariate analysis revealed that tumor bulk patients who relapse after ABMT for Hodgkin's disease. We retrospectively analyzed 68 patients with Hodgkin's was the most powerful poor prognostic factor for both survival and progression-free survival. Those transdisease who underwent ABMT at the Cleveland Clinic Foundation from January l987 to June 1993. Patients were planted with non-bulky tumors had an overall survival and progression-free survival of 52 and 44%, respecttreated with a standardized preparative regimen and survivors have been followed for a median of 5 years. We ively, compared to those transplanted with bulky tumors who had an overall survival and progressionreport not only the outcome of ABMT, but also the outcome of those who relapsed post-transplantation. free survival of 22 and 16% (P = 0.03 and P = 0.04, respectively). Twenty-seven patients have relapsed. Four relapsed more than 2 years after ABMT. Four of the 27 patients who have relapsed remain alive, two Materials and methods without evidence of disease. The time after transplant to relapse was prognostically important, with no Patient characteristics patients who relapsed within 6 months of ABMT still From January l987 to June l993, 68 patients with histologibeing alive, compared with 25% of patients who cally proven relapsed or refractory Hodgkin's disease relapsed 7 or more months after ABMT who are still underwent ABMT at the Cleveland Clinic Foundation. All alive. We conclude that salvage therapy for relapse after patients had either relapsed after initial induction chemo-ABMT is appropriate, as some patients may achieve therapy or failed to achieve complete remission with inducprolonged survival. The time from transplant to relapse tion chemotherapy. Eligibility for transplantation included a is an important survival predictor.
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amphotericin B (0.2 mg/kg per day starting on day +1). Post-transplant radiation therapy was not employed.
Statistical analysis
Time to engraftment is compared using the Wilcoxon rank sum test. Univariate survivial analysis is with the KaplanMeier method. The log rank test is used to compare curves.
A Cox proportional hazards model is used to test for independently significant risk factors for survival and relapsefree survival. 100  90  80  70  60  50  40  30  20  10  0   0  1 2  2 4  3 6  4 8  6 0  7 2  8 4  9 6 Months Survival %
Results
The median follow-up for survivors is 59 months. Overall survival for the entire group at 5 years is 43%, with an estimated median survival of 3.5 years. Progression-free survival at 5 years is 36%, with a median progression-free survival of 1.8 years.
Outcome by source of hematopoietic cells
Forty-two patients received bone marrow alone, generally before 1991. After hematopoietic growth factors became commercially available, 26 patients received growth factorprimed PBPC, with autologous marrow, followed by growth factor administration after transplantation. Engraftment characteristics of the two groups are shown in Table 2 . The accelerated neutrophil and platelet venously over 2 h given daily for 4 days on days −7, −6,
−5 and −4; and BCNU 600 mg/m 2 over 2 h on day −3).
(days) (days)
Bone marrow or PBPC was infused on day 0.
Autologous marrow alone 42
Bone marrow or PBPC processing and supportive care
Autologous marrow 26 12 18 + PBPC+G-CSF Prior to l991, patients received autologous bone marrow alone, without the infusion of post-transplant cytokines. Table 3 Outcome by tumor bulk a median survival of 30 months (range 3-61 months, P = 0.0008). stinal relapse 4 years later. He was treated with salvage chemotherapy and ABMT. Fifteen months after ABMT, he developed a mediastinal recurrence, was treated with radiation therapy and remains free of disease 48 months later. engraftment with PBPC and growth factors resulted in a significant decrease in early toxicity and mortality. Twenty-
The other patient presented with stage IIIB nodular sclerosing Hodgkin's disease, was treated with chemotherapy and one percent of patients receiving autologous bone marrow alone died within 40 days of ABMT, compared with 3.9% achieved a complete remission that lasted 6 months. He relapsed in his sacrum and was then treated with involved of those receiving autologous marrow coupled with PBPC and growth factors (P = 0.08). field radiation therapy, followed by ABMT. Seventeen months after ABMT, he had a mediastinal relapse. He was treated with radiation therapy and has remained in Prognostic factors remission for 33+ months. The other two patients who are currently alive after Several factors were examined for their impact on survival and relapse-free survival. Patient age at the time of transrelapse after ABMT have active Hodgkin's disease and are being treated with chemotherapy. One patient presented plant, sex, prior exposure to radiation therapy, number of courses of prior chemotherapy, source of autologous hemawith stage IV Hodgkin's disease and was treated with chemotherapy as well as mantle radiation therapy. He achitopoietic cells, LDH, Karnofsky score, tumor bulk, and sensitivity to chemotherapy were all included in a multivariate eved a brief partial remission, and relapsed in multiple sites within 3 months. He was treated with additional chemoCox model. Multivariate analysis revealed that tumor bulk (greater than 10 cm) was the most powerful poor prognostic therapy and ABMT. Forty-three months later, he developed recurrent Hodgkin's disease in the spleen. He is currently factor for both survival (P = 0.02) and progression-free survival (P = 0.03). The only other prognostic risk factor that responding to salvage chemotherapy. The other patient presented with stage II Hodgkin's disease and was treated was statistically significant was the use of autologous bone marrow alone (overall survival P = 0.03, progression-free with radiation therapy (mantle field). Six years later, he developed a mediastinal recurrence and was treated with survival P = 0.07). The 5-year overall survival and progression-free survival by tumor bulk are shown in Table 3 . chemotherapy and achieved a complete remission. Eighteen months later, he developed another mediastinal recurrence and was treated with salvage chemotherapy and ABMT. Relapse Eight months later, he progressed in the lung. Biopsy revealed recurrent nodular sclerosing Hodgkin's disease. Twenty-seven patients have relapsed. Eleven relapsed within 6 months of ABMT, seven relapsed 7-12 months He has since been treated with salvage chemotherapy and continues to respond. after ABMT, five patients 12-24 months after ABMT, and four patients relapsed more than 2 years after ABMT, at 25, 35, 43 and 45 months. All of the four late relapse Long-term follow-up patients had tumors of less than 10 cm.
The outcome of the 27 patients who have relapsed is Twenty-six patients remain alive and well with a median follow-up of 62 months. We have not noted the developshown in Table 4 . The median time to relapse was 6 months. Those relapsing within 6 months of ABMT experiment of myelodysplasia in any of these patients. enced a dismal prognosis. None of these patients remain alive, with a median survival after relapse of only 8 months (range 2-28 months). In contrast, 25% of the patients Discussion relapsing 7 or more months after ABMT are still alive, with Relapsed/refractory Hodgkin's disease carries a grim prognosis. 20 Initial reports describing ABMT for this patient vival of 25-50% has been described. Our overall and relapse-free survival at 5 years of 43 and 36% is compara- The main limitation of ABMT for Hodgkin's disease is disease recurrence. Excluding toxic deaths, approximately half of the patients treated in our study relapsed. Four of growth factors. [22] [23] [24] [25] [26] Our data confirm that accelerated engraftment reduces early toxicity and early mortality for these relapses occurred more than 2 years after ABMT. Several authors have also noted late relapses after transHodgkin's disease patients. Durable remission rates of 25-50% for patients with plantation. [10] [11] [12] [13] 15, 19 Of interest, all four of our patients who relapsed more than 2 years after ABMT did not have bulky relapsed Hodgkin's disease undergoing ABMT require improvement. Given that autologous transplant mortality tumors prior to transplantation. The fact that patients may be at risk of relapse for 5 years and more after autologous rates now approach 1%, strong consideration must be given to using dose-intensive therapy earlier in the course of the transplantation demonstrates the importance of continued clinical monitoring of this transplant population. Periodic disease in high-risk patients. Reece et al 27 recently described a series of 30 Hodgkin's disease patients who did history and physical examinations, coupled with appropriate radiologic surveillance, is warranted years after ABMT. not achieve complete remission and proceeded directly to autologous transplantation. Half of the transplanted patients Four of our patients who have relapsed remain alive, two without evidence of disease after receiving radiation therremain in remission 3.6 years post-transplant. The importance of identifying high-risk Hodgkin's disease patients at apy as salvage treatment, and two continue to receive chemotherapy. Vose et al 21 reported 95 patients with Hodgdiagnosis cannot be overemphasized. Such high-risk patients are clearly candidates for clinical research protokin's disease relapsing after ABMT. The median survival after relapse was 10.5 months. Ten remained alive at the cols involving dose-intensive therapy with autologous transplantation. This strategy may well be the optimal strattime of the report, although only four had been followed for longer than 1 year after relapse. The time from transplant to egy for favorable impact in this patient population. relapse did not influence survival of the relapsed patient population. This was in contrast to data reported in the References same article concerning outcome of relapsed non-Hodgkin's lymphoma patients after ABMT, in which the time 
